CTMX
CytomX Therapeutics Inc
NASDAQ: CTMX · HEALTHCARE · BIOTECHNOLOGY
$3.29
-1.79% today
Updated 2026-09-11
Market cap
$716.89M
P/E ratio
—
P/S ratio
39.17x
EPS (TTM)
$-0.57
Dividend yield
—
52W range
$2 – $8
Volume
3.0M
CytomX Therapeutics Inc (CTMX) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$3.29
12-Month target
—
2030 Target
—
Intrinsic (DCF)
$3.14
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B | $0.1B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 2.18% (capped 20%) · P/E: 25.00x (capped 25x) · Margin: 0.00%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.